ライフサイエンスコーパス: gastroesophageal reflux

1 , abdominal pain, diarrhea, weight loss, and gastroesophageal reflux.

2 esophagus and may work synergistically with gastroesophageal reflux.

3 criteria and two with findings secondary to gastroesophageal reflux.

4 leaks and strictures, gastric dilation, and gastroesophageal reflux.

5 Barrett's esophagus segments and persistent gastroesophageal reflux.

6 frequently performed surgical procedure for gastroesophageal reflux.

7 fundoplication for the surgical treatment of gastroesophageal reflux.

8 choanal atresia repair, and/or treatment of gastroesophageal reflux.

9 gher scores indicating better function), and gastroesophageal reflux.

10 ergone a fundoplication for the treatment of gastroesophageal reflux.

11 The symptoms are often confused for those of gastroesophageal reflux.

12 esophageal diseases result from uncontrolled gastroesophageal reflux.

13 hincter relaxation is the main mechanism for gastroesophageal reflux.

14 sociated with a two-to threefold increase in gastroesophageal reflux.

15 n, poor overall health, home oxygen use, and gastroesophageal reflux.

16 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 point), and depression (+1 p

17 omorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasa

18 ocephaly, developed intellectual disability, gastroesophageal reflux and a seizure disorder.

19 There were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses o

20 tissue remodeling is associated with chronic gastroesophageal reflux and constitutes a premalignant l

21 BE is associated with chronic gastroesophageal reflux and esophageal cancer.

22 because of both mechanical effects promoting gastroesophageal reflux and nonmechanical effects.

23 also significant improvements in symptoms of gastroesophageal reflux and rhinitis, bronchial reversib

24 wn a positive correlation between pathologic gastroesophageal reflux and those with hiatal hernia or

25 index greater than 4 on pH monitoring and/or gastroesophageal reflux and/or herniated wrap on upper g

26 Infantile colic, gastroesophageal reflux, and constipation are the most c

27 y causes symptoms similar to those seen with gastroesophageal reflux, and is characterized by increas

28 pse include neck flexion, airway secretions, gastroesophageal reflux, and sleep deprivation.

29 ralized anxiety disorder, diabetes mellitus, gastroesophageal reflux, bacterial infection, and bone m

30 is used variably to prevent complications of gastroesophageal reflux, but its effectiveness is unprov

31 ment of patients who fail medical therapy of gastroesophageal reflux, but recurrent gastroesophageal

32 Nissen fundoplication for gastroesophageal reflux can be followed by troublesome s

33 Gastroesophageal reflux causes inflammation and intestin

34 trophy (SMA) notes that patients suffer from gastroesophageal reflux, constipation and delayed gastri

35 ng bowel habit (15%), constipation (13%) and gastroesophageal reflux disease (12%).

36 lipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease (17.3%).

37 The presence of gastroesophageal reflux disease (26%), esophageal strict

38 ere rhinitis (84.0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

39 gus (n = 1059) with those from subjects with gastroesophageal reflux disease (gastroesophageal reflux

40 .1; 95% confidence interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI,

41 lin, leptin, and ghrelin are associated with gastroesophageal reflux disease (GERD) and Barrett's eso

42 We examined the incidence and predictors of gastroesophageal reflux disease (GERD) and dyspepsia and

43 and evaluate esophageal disorders, including gastroesophageal reflux disease (GERD) and eosinophilic

44 Skinner to the understanding of gastroesophageal reflux disease (GERD) and its complicat

45 might represent an alternative treatment of gastroesophageal reflux disease (GERD) and may provide d

46 has enormous potential for the treatment of gastroesophageal reflux disease (GERD) and other esophag

47 The advent of the Montreal definition of gastroesophageal reflux disease (GERD) and the Rome III

48 agement of extraesophageal manifestations of gastroesophageal reflux disease (GERD) and to compare th

49 Lung transplant recipients with documented gastroesophageal reflux disease (GERD) are at increased

50 Current diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal an

51 hageal eosinophilia who were thought to have gastroesophageal reflux disease (GERD) but who did not r

52 Management of gastroesophageal reflux disease (GERD) commonly starts w

53 t clear why only a minority of patients with gastroesophageal reflux disease (GERD) develop Barrett's

54 .4)] were included; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

55 However, gastroesophageal reflux disease (GERD) has remained the

56 surgery, highly variable rates of recurrent gastroesophageal reflux disease (GERD) have been reporte

57 The histologic changes associated with acute gastroesophageal reflux disease (GERD) have not been stu

58 The prevalence of gastroesophageal reflux disease (GERD) in Africa is not

59 The aim was to compare recurrence of gastroesophageal reflux disease (GERD) in children rando

60 RAs) are frequently used in the treatment of gastroesophageal reflux disease (GERD) in children; howe

61 ull-thickness plication for the treatment of gastroesophageal reflux disease (GERD) in comparison wit

62 n (TF) can decrease or eliminate features of gastroesophageal reflux disease (GERD) in some patients

63 There are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United Sta

64 Gastroesophageal reflux disease (GERD) increases EAC ris

65 Gastroesophageal reflux disease (GERD) is a chronic diso

66 Gastroesophageal reflux disease (GERD) is a common comor

67 Gastroesophageal reflux disease (GERD) is a common diagn

68 Gastroesophageal reflux disease (GERD) is a common medic

69 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor

70 Gastroesophageal reflux disease (GERD) is a very common

71 Gastroesophageal reflux disease (GERD) is associated wit

72 Endoscopic management of gastroesophageal reflux disease (GERD) is being employed

73 Gastroesophageal reflux disease (GERD) is caused by gast

74 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and in

75 Gastroesophageal reflux disease (GERD) is defined by rec

76 illustrated by the Montreal classification, gastroesophageal reflux disease (GERD) is much more than

77 Gastroesophageal reflux disease (GERD) is prevalent worl

78 ump inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) is reported in up

79 Gastroesophageal reflux disease (GERD) is the most commo

80 Gastroesophageal reflux disease (GERD) is the most preva

81 Gastroesophageal reflux disease (GERD) is the strongest

82 Many individuals with gastroesophageal reflux disease (GERD) never visit their

83 f an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it pre

84 Refractory gastroesophageal reflux disease (GERD) reduces quality o

85 Most patients with gastroesophageal reflux disease (GERD) report that stres

86 Gastroesophageal reflux disease (GERD) seems to increase

87 has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite

88 assessed the utility of NBI in patients with gastroesophageal reflux disease (GERD) symptoms.

89 Patients with gastroesophageal reflux disease (GERD) who are not respo

90 phagus (cases) were matched to subjects with gastroesophageal reflux disease (GERD) without Barrett's

91 tailed critique of objective measurements of gastroesophageal reflux disease (GERD) would improve man

92 BS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD), 9.7.

93 cluding Crohn disease (CrD), celiac disease, gastroesophageal reflux disease (GERD), and eosinophilic

94 frequency of irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive b

95 e upper airways dysfunction syndrome (RUDS), gastroesophageal reflux disease (GERD), and rare cases o

96 rm use of PPIs for three common indications: gastroesophageal reflux disease (GERD), Barrett's esopha

97 this study was to appraise the prevalence of gastroesophageal reflux disease (GERD), esophagitis, and

98 n several pathophysiological states, such as gastroesophageal reflux disease (GERD), functional dyspe

99 Gastroesophageal reflux disease (GERD), functional dyspe

100 Barrett esophagus, a complication of gastroesophageal reflux disease (GERD), predisposes pati

101 ients, who had a previous fundoplication for gastroesophageal reflux disease (GERD), underwent reoper

102 ed the accuracy of frequency and duration of gastroesophageal reflux disease (GERD), using data from

103 Gastroesophageal reflux disease (GERD), which leads to a

104 Unlike gastroesophageal reflux disease (GERD), whose symptoms c

105 can individuals have a similar prevalence of gastroesophageal reflux disease (GERD), yet esophageal a

106 defined as a decrease of 50% or more in the Gastroesophageal Reflux Disease (GERD)-Health Related Qu

107 responders and treatment-naive patients with gastroesophageal reflux disease (GERD).

108 n accurate method for diagnosing adults with gastroesophageal reflux disease (GERD).

109 s for a range of medical disorders including gastroesophageal reflux disease (GERD).

110 only used in the diagnosis and management of gastroesophageal reflux disease (GERD).

111 ctional gastrointestinal disorders (FGD) and gastroesophageal reflux disease (GERD).

112 e existing endoscopy-based interventions for gastroesophageal reflux disease (GERD).

113 a significant increase in the prevalence of gastroesophageal reflux disease (GERD).

114 a novel device for the surgical treatment of gastroesophageal reflux disease (GERD).

115 in the past year has centered on surgery for gastroesophageal reflux disease (GERD).

116 on atypical/extraesophageal manifestation of gastroesophageal reflux disease (GERD).

117 halasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (GERD).

118 one combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD).

119 en fundoplication (CNF) for the treatment of gastroesophageal reflux disease (GERD).

120 dal anti-inflammatory drugs) and symptoms of gastroesophageal reflux disease (GERD).

121 urgical option for patients with early-stage gastroesophageal reflux disease (GERD).

122 procedure of choice for obese patients with gastroesophageal reflux disease (GERD).

123 y risk factors for both BE and EA is chronic gastroesophageal reflux disease (GERD).

124 cations in adults were dysphagia (70.1%) and gastroesophageal reflux disease (GERD)/heartburn (27.1%)

125 We also included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 w

126 n 2002 and 2005 were matched to persons with gastroesophageal reflux disease (GERD; n = 316) and to p

127 Gastroesophageal reflux disease (GORD) is a chronic and

128 nths after fundoplication for PPI-refractory gastroesophageal reflux disease (n = 14 270 degrees LPF

129 (n = 296 cases) were matched to persons with gastroesophageal reflux disease (n = 308) without Barret

130 ad EoE (n = 17), indeterminate EoE (n = 15), gastroesophageal reflux disease (n = 7), or normal esoph

131 Glasgow Coma Scale score <9 (p = .021), and gastroesophageal reflux disease (p = .033).

132 onitoring on therapy in patients with proven gastroesophageal reflux disease [GERD]), to document phy

133 ether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting,

134 uency, severity, and duration of symptoms of gastroesophageal reflux disease among randomly selected

135 er improvement in quality of life related to gastroesophageal reflux disease and a 50% or greater red

136 rs to result in decreased prevalence of both gastroesophageal reflux disease and adenocarcinoma of th

137 patterns from biopsies of patients with EoE, gastroesophageal reflux disease and controls.

138 ulosis is associated with conditions such as gastroesophageal reflux disease and diabetes mellitus, a

139 allenges to diagnosis, including the role of gastroesophageal reflux disease and proton pump inhibito

140 75-year-old woman with a medical history of gastroesophageal reflux disease and type II diabetes pre

141 e mechanisms involved in the pathogenesis of gastroesophageal reflux disease are complex and multifac

142 The high reoperation rate and incidence of gastroesophageal reflux disease are concerning.

143 pump inhibitors and has focused attention on gastroesophageal reflux disease as a causative factor in

144 We prospectively assessed 100 patients with gastroesophageal reflux disease before and after sphinct

145 iteria consisted of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophagea

146 , screening 50-year-old men with symptoms of gastroesophageal reflux disease by Cytosponge is cost ef

147 emerging disease that is distinguished from gastroesophageal reflux disease by the expression of a u

148 suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures.

149 Gastroesophageal reflux disease complicated by Barrett e

150 Gastroesophageal reflux disease complicated by Barrett's

151 search into the use of these technologies in gastroesophageal reflux disease continues to accelerate,

152 95% confidence interval [CI]: 1.04-2.67) or gastroesophageal reflux disease controls (OR = 1.61; 95%

153 bjects with gastroesophageal reflux disease (gastroesophageal reflux disease controls, n = 1332), and

154 Early aggressive surgical treatment of gastroesophageal reflux disease decreases the rate of br

155 es for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive

156 ugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, a

157 ecome available in the last 2 years for many gastroesophageal reflux disease endotherapies, providing

158 Most patients with gastroesophageal reflux disease experience symptomatic r

159 rm outcome of ARS in pediatric patients with gastroesophageal reflux disease have shown good to excel

160 months improved in patients with normal GE (Gastroesophageal Reflux Disease Health-Related Quality o

161 imary laparoscopic antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

162 BMI is associated with symptoms of gastroesophageal reflux disease in both normal-weight an

163 ed strong genetic correlations of BE/EA with gastroesophageal reflux disease in male individuals and

164 re of the height in meters - and symptoms of gastroesophageal reflux disease in persons of normal wei

165 related to the acidic environment caused by gastroesophageal reflux disease in the gastroesophageal

166 Gastroesophageal reflux disease is a common clinical pro

167 Gastroesophageal reflux disease is a highly prevalent ch

168 Gastroesophageal reflux disease is a highly prevalent di

169 w endoscopic therapies have emerged to treat gastroesophageal reflux disease itself.

170 esophageal sphincter (LES) in patients with gastroesophageal reflux disease often has a low resting

171 is (EoE) was historically distinguished from gastroesophageal reflux disease on the basis of histolog

172 ated with EoE (or indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and

173 Diagnosis of GERD was by means of the gastroesophageal reflux disease questionnaire (GERDQ) wh

174 Endoscopic therapies for gastroesophageal reflux disease represent a minimally in

175 ted with a relatively high rate of recurrent gastroesophageal reflux disease requiring treatment, dim

176 Symptoms improved in group A, with the Gastroesophageal Reflux Disease Symptom Assessment Scale

177 racticed, its value in patients with chronic gastroesophageal reflux disease symptoms is of unproven

178 ng upper endoscopy for patients with chronic gastroesophageal reflux disease symptoms to assess for B

179 men in the United Kingdom with histories of gastroesophageal reflux disease symptoms, assuming the p

180 The history of gastroesophageal reflux disease was highly prevalent in

181 Gastroesophageal reflux disease was identified as an imp

182 De novo gastroesophageal reflux disease was reported in 43.8%.

183 screening ages for patients with symptomatic gastroesophageal reflux disease were older (58 for men a

184 as chronic sinusitis, allergic rhinitis, and gastroesophageal reflux disease were only associated wit

185 Patients with gastroesophageal reflux disease who have a partial respo

186 structive sleep apnea may be associated with gastroesophageal reflux disease, a strong risk factor fo

187 allergic rhinitis, chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep

188 Risk factors evaluated included gastroesophageal reflux disease, alcohol consumption, sm

189 ibly due to increased abdominal pressure and gastroesophageal reflux disease, although this pathogeni

190 lization for asthma, mechanical ventilation, gastroesophageal reflux disease, and aspiration or other

191 lation), and prior diagnoses (eg, pneumonia, gastroesophageal reflux disease, and other comorbidities

192 the individual to irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer diseas

193 treat a variety of gastric disorders such as gastroesophageal reflux disease, autoimmune gastritis, g

194 factors for EAC have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, ob

195 shown to be a safe and effective therapy for gastroesophageal reflux disease, but its effect on the L

196 Symptoms frequently mimic those of gastroesophageal reflux disease, but the diseases are di

197 Risk factors include gastroesophageal reflux disease, central obesity, and sm

198 sing and treating chest pain associated with gastroesophageal reflux disease, correlates abnormal amb

199 terms: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

200 lowing: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

201 l gastrointestinal complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Ba

202 This issue provides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis,

203 of the lower esophagus epithelium related to gastroesophageal reflux disease, is the strongest known

204 a diligent search for an esophageal etiology-gastroesophageal reflux disease, motility abnormalities,

205 itant chemical carcinogen treatment leads to gastroesophageal reflux disease, multilayered epithelium

206 With improved understanding of gastroesophageal reflux disease, newer developments in d

207 on airway disease, including rhinosinusitis, gastroesophageal reflux disease, obesity and dysfunction

208 , including history of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal ble

209 This article is a review of gastroesophageal reflux disease, other types of esophagi

210 Too much acid can lead to gastroesophageal reflux disease, peptic ulcer disease, a

211 premorbid prevalence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infect

212 44 patients (52%) had objective findings of gastroesophageal reflux disease, such as esophagitis.

213 Triggered by gastroesophageal reflux disease, the origin of this meta

214 ic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabet

215 Except for gastroesophageal reflux disease, which showed a higher r

216 ministered a modified version of a validated gastroesophageal reflux disease-specific QOL tool to pat

217 Quality of life, measured by the gastroesophageal reflux disease-specific QOL tool, and r

218 ery effective and long-lasting treatment for gastroesophageal reflux disease.

219 Obesity is associated with a risk of gastroesophageal reflux disease.

220 llow-up after ARS in pediatric patients with gastroesophageal reflux disease.

221 180-degree LAF for the surgical treatment of gastroesophageal reflux disease.

222 st frequently performed surgical therapy for gastroesophageal reflux disease.

223 ved cells is a novel potential treatment for gastroesophageal reflux disease.

224 drome (IBS) frequently overlap with those of gastroesophageal reflux disease.

225 gents widely prescribed for the treatment of gastroesophageal reflux disease.

226 to evaluate for the presence of concomitant gastroesophageal reflux disease.

227 thereby conclusively distinguishing it from gastroesophageal reflux disease.

228 fundoplication is an effective treatment for gastroesophageal reflux disease.

229 places esophageal squamous mucosa damaged by gastroesophageal reflux disease.

230 increasingly recognized disease that mimics gastroesophageal reflux disease.

231 ders, including irritable bowel syndrome and gastroesophageal reflux disease.

232 ct patients from developing complications of gastroesophageal reflux disease.

233 itis is a new disease commonly confused with gastroesophageal reflux disease.

234 esophageal motor disorders and treatment of gastroesophageal reflux disease.

235 the association between BMI and symptoms of gastroesophageal reflux disease.

236 relation to the occurrence and management of gastroesophageal reflux disease.

237 and obese persons are at increased risk for gastroesophageal reflux disease.

238 actors usually indicative of severe types of gastroesophageal reflux disease.

239 d-mediated event and a reliable indicator of gastroesophageal reflux disease.

240 directions in the research and treatment of gastroesophageal reflux disease.

241 eading to duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease.

242 the AGA Institute on "Endoscopic Therapy for Gastroesophageal Reflux Disease." It was approved by the

243 is a laryngeal symptom that can be caused by gastroesophageal reflux disease; however, treatment outc

244 cough may have abnormal proximal exposure to gastroesophageal reflux documented by HMII that would ha

245 Gastroesophageal reflux/dysphagia and asthma/rhinitis re

246 ers, including nonalcoholic steatohepatitis, gastroesophageal reflux, gallstones, and increased risk

247 The contribution of gastroesophageal reflux (GER) and vagal function to esop

248 Dental erosion is a complication of gastroesophageal reflux (GER) in adults; in children, it

249 Gastroesophageal reflux (GER) is a disorder that is comm

250 The prevalence of abnormal acid gastroesophageal reflux (GER) is higher in patients with

251 Asymptomatic gastroesophageal reflux (GER) is prevalent in children w

252 f a disease engendered more controversy than gastroesophageal reflux (GER), a highly prevalent condit

253 symptom relief, prevalence of post-treatment gastroesophageal reflux (GER), and complications.

254 sts with erosive tooth wear have significant gastroesophageal reflux (GERD), despite minor reflux sym

255 n the temporal association between cough and gastroesophageal reflux (GOR) in patients in whom non-GO

256 laparoscopically but failure with recurrent gastroesophageal reflux has resulted in the development

257 tocompatibility locus antigen antibodies and gastroesophageal reflux have been associated with poor o

258 sphincter (UES) to simulated or spontaneous gastroesophageal reflux have shown conflicting results.

259 Subjects reporting nocturnal gastroesophageal reflux in both 1999 and 2010 had more N

260 For the first time, mechanisms of gastroesophageal reflux in critically ill mechanically v

261 rtburn with and without regurgitation due to gastroesophageal reflux in the absence of esophageal muc

262 py of gastroesophageal reflux, but recurrent gastroesophageal reflux is a persistent problem that req

263 Gastroesophageal reflux is common among patients with po

264 he diagnosis of cough, LPR, or asthma due to gastroesophageal reflux is difficult, as no criterion st

265 Gastroesophageal reflux is the main risk factor for esop

266 allograft injury from donor-directed Abs or gastroesophageal reflux led to new ColV and KAT Abs post

267 discussed: rhinitis, chronic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal

268 As gastroesophageal reflux persists or recurs in 43% of chi

269 There is significant though mild gastroesophageal reflux postoperatively in 46% of patien

270 rative complications, sleep difficulties and gastroesophageal reflux progressively worsened during fo

271 in the postoperative period from SSc-related gastroesophageal reflux, renal impairment, and skin fibr

272 ireflux surgery, 17.7% experienced recurrent gastroesophageal reflux requiring long-term medication u

273 poorly described, and the risk of worsening gastroesophageal reflux requiring revision may be higher

274 Gastroesophageal reflux scores were higher in overweight

275 , sex, percent predicted FEV1, self-reported gastroesophageal reflux, St. George's Respiratory Questi

276 presenting with extra-esophageal symptoms of gastroesophageal reflux such as chronic cough and asthma

277 t questionnaire was considered diagnostic of gastroesophageal reflux symptoms (GERD).

278 based on the modified Rome III criteria) and gastroesophageal reflux symptoms (GERS) in a population-

279 Apoptosis pathway, gastroesophageal reflux symptoms (reflux), higher body m

280 eep apnea and to determine whether nocturnal gastroesophageal reflux symptoms affect the relationship

281 estioned regarding severity of their typical gastroesophageal reflux symptoms and presence of nocturn

282 nal GERD in 1999 (>/=3 episodes of nocturnal gastroesophageal reflux symptoms per week) had an OR of

283 Barrett's esophagus patients with nocturnal gastroesophageal reflux symptoms should be further evalu

284 's esophagus was associated with more severe gastroesophageal reflux symptoms, and nocturnal reflux s

285 al reflux symptoms and presence of nocturnal gastroesophageal reflux symptoms.

286 ymptom control in up to 50% of patients with gastroesophageal reflux symptoms.

287 The rate of gastroesophageal reflux was comparable with prior studie

288 Gastroesophageal reflux was defined by abnormal pH-testi

289 At 6 months, gastroesophageal reflux was evaluated by 24-hour pH test

290 Gastroesophageal reflux was more common among patients w

291 Gastroesophageal reflux was reported in 50.0% (40 vs 27

292 Objective evidence of gastroesophageal reflux was seen in 46% patients postope

293 Gastroesophageal reflux was the most common GI diagnosis

294 Chronic sinusitis and gastroesophageal reflux were also associated with exacer

295 From 1995 to 2003, 461 patients with gastroesophageal reflux were enrolled in 4 randomized co

296 pump inhibitors (PPIs) are popular drugs for gastroesophageal reflux, which are now available for lon

297 BACKGROUND & AIMS: Central obesity promotes gastroesophageal reflux, which may be related to increas

298 s have failed to demonstrate that preventing gastroesophageal reflux with antireflux surgery halts th

299 f unproven efficacy and focus on controlling gastroesophageal reflux with reflux-reducing medication

300 Six studies have suggested that gastroesophageal reflux worsens after cholecystectomy.